简
繁
EN
简
繁
EN
HOME
·
submission
AI medical unicorn Hangzhou Diagens Biotechnology Co., Ltd. makes a second attempt to list on the Hong Kong Stock Exchange: backed by the world's first medical imaging large model, with a 30.6% market share ranking first
Tags：
Hangzhou Diagens Biotechnology Co., Ltd.
IPO
submission
AI medical care
2026-01-07
Featured News
Finance
XIAOMI-W(01810.HK) will spend HKD 190.58 million to repurchase 5 million shares on Jan 8, 2026
Finance
S HARBOURHOLD (01663.HK): Wang Linbing Increases Stake with 11.95 Million Shares Purchased
Finance
GEELY AUTO(00175.HK) will spend HKD 67.62 million to repurchase 3.93 million shares on Jan 8, 2026
Finance
TENCENT(00700.HK) will spend HKD 635.62 million to repurchase 1.03 million shares on Jan 8, 2026
ETF
Csop Coinbase Daily (-2x) Inverse Product (07311.HK) rose over 7%! Leveraged layout to seize the opportunity from the volatility of Coinbase Global's market
ETF
CSOP MicroStrategy Daily (-2x) Inverse Product (07399.HK) rose strongly by over 11%, with a 2x inverse exposure to U.S. stock MicroStrategy
ETF
Global X China MedTech ETF (02841.HK) has risen more than 7% since the beginning of the year, focusing on China's medical technology industry
ETF
Premia China STAR50 ETF (03151.HK) rose more than 2% at one point intraday, a powerful tool for Hong Kong stock market to deploy high-quality assets in A-share hard technology
ETF
Penghua CSI Subdivision Chemical Industry Theme ETF(159870) Falls 1.39%, Attracts 1.827 Billion Yuan Over Past 5 Days
ETF
Guotai CSI All Share building Materials ETF(159745) Rises 0.90% Against the Trend, Scale Grows 175 Million Yuan Over Past Half Year
